Drugs that contain Metformin Hydrochloride; Pioglitazone Hydrochloride
1. Actoplus Met patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6172090 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6166042 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6166043 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US5965584 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US9101660 | TAKEDA PHARMS USA | Solid preparation |
Jan, 2027
(2 years from now) | |
| US9320714 | TAKEDA PHARMS USA | Tablet |
Feb, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-116) | May 17, 2015 |
Market Authorisation Date: 29 August, 2005
Treatment: Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are already treated with a pioglitazone and metformin; An adjunct to diet and exercise to improve glycemic...
Dosage: TABLET;ORAL
ACTOPLUS MET family patents
2. Actoplus Met Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5965584 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6166043 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6172090 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6166042 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US8475841 | TAKEDA PHARMS USA | Controlled release metformin formulations |
Mar, 2018
(6 years ago) | |
| US6099859 | TAKEDA PHARMS USA | Controlled release oral tablet having a unitary core |
Mar, 2018
(6 years ago) | |
| US6495162 | TAKEDA PHARMS USA | Controlled release oral tablet having a unitary core |
Mar, 2018
(6 years ago) | |
| US7919116 | TAKEDA PHARMS USA | Controlled release metformin formulations |
Mar, 2018
(6 years ago) | |
| US6790459 | TAKEDA PHARMS USA | Methods for treating diabetes via administration of controlled release metformin |
Mar, 2021
(3 years ago) | |
| US6866866 | TAKEDA PHARMS USA | Controlled release metformin compositions |
Mar, 2021
(3 years ago) | |
| US8470368 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(6 months ago) | |
| US8668931 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(6 months ago) | |
| US9060941 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(6 months ago) | |
| US7785627 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Jul, 2026
(2 years from now) | |
| US7959946 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Jul, 2026
(2 years from now) | |
Market Authorisation Date: 12 May, 2009
Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with pioglitazone and metformin or who have inadequate glycemic control on piog...
Dosage: TABLET, EXTENDED RELEASE;ORAL
ACTOPLUS MET XR family patents